Hjem › Tripelnegativ brystkreft › Florida › Tampa
Kliniske studier for Tripelnegativ brystkreft i Tampa, FL
15 studier for Tripelnegativ brystkreft søker deltakere på steder i og rundt Tampa (innen ca. 30 miles). Åpne et studie for å se hvem som kan delta og hvordan du kontakter studieteamet.
Offisiell studietekst (engelsk)
Rekrutterer til et studie her? Få det fremtredende øverst på siden – $99 i 30 dager →
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekruttererFase 1/2
- Avenzo Therapeutics Recruiting Site, Tampa
Solid Tumor Analysis for HLA Loss of Heterozygosity (LOH) and Apheresis for CAR T- Cell Manufacturing
RekruttererObservasjonsstudie
- Moffitt Cancer Center, Tampa
Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer
RekruttererFase 2
- Moffitt Cancer Center, Tampa
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
RekruttererFase 1
- Moffitt Cancer Center, Tampa
Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
RekruttererFase 2
- Moffitt Cancer Center-International Plaza, Tampa
- Moffitt Cancer Center - McKinley Campus, Tampa
- Moffitt Cancer Center, Tampa
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
RekruttererFase 1
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
RekruttererFase 1/2
- Moffitt Cancer Center and Research Institute, Tampa
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RekruttererFase 2
- H. Lee Moffitt Cancer Center and Research Institute, Tampa
- Moffitt Cancer Center, Tampa
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
RekruttererTidlig fase 1
- Moffitt Cancer Center, Tampa
DecipHER Trial - DC1 Tx for Early-Stage TNBC and ER Low Positive Breast Cancer
RekruttererFase 1
- Moffitt Cancer Center, Tampa
Sacituzumab Govitecan and Zimberelimab w/SRS in the Management of Metastatic Triple Negative Breast Cancer With Brain Metastases
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
A Phase 2 Study of PCS6422 With Capecitabine in Patients With Advanced or Metastatic Breast Cancer
RekruttererFase 2
- Moffitt Cancer Center, Tampa
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
RekruttererFase 1/2
- Moffitt Cancer Center, Tampa
Tripelnegativ brystkreft-studier i andre byer
- Houston, TX42 studier
- New York City, NY31 studier
- Nashville, TN28 studier
- Los Angeles, CA27 studier
- Boston, MA26 studier
- San Antonio, TX23 studier
- St. Louis, MO21 studier
- Arlington, VA20 studier
- Atlanta, GA20 studier
- Dallas, TX18 studier
- Chicago, IL16 studier
- Columbus, OH16 studier
Andre studier i Tampa
- Ikke-småcellet lungekreft51 studier
- Brystkreft43 studier
- Kreft (alle typer)39 studier
- Kolorektal kreft34 studier
- Akut myelogen leukemi29 studier
- Metastatisk kreft29 studier
- Lungekreft29 studier
- Pankreaskreft26 studier
- Eggstokkreft21 studier
- Melanom19 studier
- Myelodysplastiske syndromer19 studier
- Prostatakreft18 studier
Fra ClinicalTrials.gov, data hentet 6. okt. 2026. Hver studie setter sine egne kvalifikasjonskrav; studieteamet avgjør hvem som kan delta.